Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.
Phase 2
- Conditions
- cutaneous cGVHD.Graft-versus-host reaction or disease
- Registration Number
- IRCT201302261030N12
- Lead Sponsor
- Hematology-Oncology and SCT Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Inclusion Criteria
1- The patient shall undergo allogen bone marrow transplantation and have clinical and pathological cutaneous CGVHD criteria.
2- Patient’s cutaneous signs are not improved by taking corticosteroids with doses of 0.5 mg/kg at least for 3 months and cyclosporine.
3- The cutaneous signs shall be active.
4- The patient shall be aged between 16 to 60 years old.
Exclusion Criteria
1- Pregnancy
2- Having a history of taking Rituximab.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The extent of cutaneous involvment. Timepoint: At the start of treatment and in the end of 6 month. Method of measurement: Skin examination.
- Secondary Outcome Measures
Name Time Method Extent of skin involvement in pathology. Timepoint: At the start of treatment and in the end of 6 month. Method of measurement: Severity of involvement in pathology.;Side effect frequency. Timepoint: Every month after treatment up to 6 months. Method of measurement: Examination and fallowing treatment.